Licochalcone B

Research use only, not for human use.

Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model.

Licochalcone B (LCB) inhibits the proliferation of human malignant bladder cancer cell lines (T24 and EJ) in vitro and antitumor activity in vivo in MB49 (murine bladder cancer cell line) tumor model. LCB and Licochalcone D(LCD) significantly reduced the LPS-induced production of NO, TNFalpha and MCP-1. A novel LCB derivative compound: (E)-3-(3, 4-dihydroxy-2-methoxyphenyl)-1-(2, 4-dihydroxyphenyl)prop-2-en-1-one inhibits inflammatory reactions in macrophages and protects mice from endotoxin shock.

Western Blot Analysis Cell Line:RAW264.7 cells Concentration:10 μM Incubation Time:1 h Result:Inhibited the phosphorylation of NF-κB at serine 276 but not at serine 536.

Animal Model:Mice induced by CCl4 Dosage:1, 5, 25 mg/kg Administration:Oral gavage.Result:Elevated the levels of SOD and GSH, and reduced the GSSG levels.

Licochalcone B | Licochalcone-B

Others

Other Targets

Others

——

——

58749-23-8

286.28

C16H14O5

>98% (HPLC)

In Vitro:?DMSO : 83.33 mg/mL (291.08 mM)

COC1=C(C=CC(=C1O)O)C=CC(=O)C2=CC=C(C=C2)O

(E)-1-(3,4-dihydroxy-2-methoxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one

(-20℃)

With Ice Pack

≥ 2 years